WASHINGTON--(BUSINESS WIRE)--Provisions in the Patent Reform Act of 2007 (S. 1145) would unintentionally promote uncertainty surrounding – and weaken the enforceability of – validly issued patents, testified a representative of the Biotechnology Industry Organization (BIO) before a congressional committee today. Appearing on behalf of BIO, Alkermes, Inc. Senior Vice President and General Counsel Kathryn Biberstein outlined the organization’s views on patent reforms and its specific concerns with S. 1145 in testimony delivered before a hearing held by the Judiciary Committee of the United States Senate.
